LEXINGTON, Mass.--(BUSINESS WIRE)--Translate Bio, Inc. (Nasdaq: TBIO) a clinical-stage messenger RNA (mRNA) therapeutics company developing a new class of potentially transformative medicines to treat diseases caused by protein or gene dysfunction, today announced the pricing of its initial public offering of 9,350,000 shares of its common stock at a price to the public of $13.00 per share, for total gross proceeds of approximately $121.6 million, before deducting underwriting discounts and commissions and expenses payable by Translate Bio. In addition, Translate Bio has granted the underwriters a 30-day option to purchase up to 1,402,500 additional shares of common stock at the public offering price, less underwriting discounts and commissions, to cover over-allotments, if any. All of the shares are being offered by Translate Bio. The shares are expected to begin trading on the Nasdaq Global Select Market on June 28, 2018 under the symbol “TBIO.” The offering is expected to close on July 2, 2018, subject to customary closing conditions.
Citigroup, Leerink Partners and Evercore ISI are acting as joint book-running managers for the offering.
A registration statement relating to the shares being sold in this offering was declared effective by the Securities and Exchange Commission on June 27, 2018. The offering is being made only by means of a prospectus. When available, a copy of the final prospectus may be obtained by contacting Citigroup Global Markets Inc. c/o Broadridge Financial Solutions, 1155 Long Island Avenue, Edgewood, NY 11717 or by telephone at 1-800-831-9146; Leerink Partners LLC, Attention: Syndicate Department, One Federal Street, 37th Floor, Boston, MA 02110, by telephone at 1-800-808-7525, ext. 6132, or by email at syndicate@leerink.com; or Evercore Group L.L.C., Attention: Equity Capital Markets, 55 East 52nd Street, 36th Floor, New York, New York 10055, by telephone at 888-474-0200, or by email at ecm.prospectus@evercore.com.
This press release shall not constitute an offer to sell, or a solicitation of an offer to buy these securities, nor shall there be any sale of, these securities in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction.
About Translate Bio
Translate Bio is a clinical-stage mRNA
therapeutics company developing a new class of potentially
transformative medicines to treat diseases caused by protein or gene
dysfunction.
Forward-Looking Statements
Statements in this press release
about future expectations, plans and prospects, as well as any other
statements regarding matters that are not historical facts, may
constitute “forward-looking statements” within the meaning of The
Private Securities Litigation Reform Act of 1995. These statements
include, but are not limited to, statements relating to the expected
trading commencement and closing dates. The words “anticipate,”
“believe,” “continue,” “could,” “estimate,” “expect,” “intend,” “may,”
“plan,” “potential,” “predict,” “project,” “should,” “target,” “will,”
“would” and similar expressions are intended to identify forward-looking
statements, although not all forward-looking statements contain these
identifying words. Actual results may differ materially from those
indicated by such forward-looking statements as a result of various
important factors, including: the uncertainties related to market
conditions and the completion of the public offering on the anticipated
terms or at all, and other factors discussed in the “Risk Factors”
section of the preliminary prospectus filed with the Securities and
Exchange Commission. Any forward-looking statements contained in this
press release speak only as of the date hereof, and Translate Bio
specifically disclaims any obligation to update any forward-looking
statement, whether as a result of new information, future events or
otherwise.
